Entest CEO Blogcast Today at 10:00 am Covering Strategic Rollout of ImenVax(TM) -- an Immuno-Therapeutic Cancer Vaccine for Dogs

/ Source: GlobeNewswire

Update to Include Strategy on Acquiring Veterinary Clinics for Immediate Revenue Generation and New Sales Channel for Veterinary Therapies

Blogcast Scheduled for Today, September 21st at 10:00 am PDT

SAN DIEGO, Sept. 21, 2010 (GLOBE NEWSWIRE) -- Entest BioMedical, Inc. (OTCBB:ENTB) announced that Chairman and CEO David Koos will be hosting a blogcast today, September 21, 2010 at 10:00 am PDT. Discussion will focus on developments related to the Company's immuno-therapeutic cancer vaccine for dogs, ImenVax™. Areas to be covered include:

a) ImenVax's™ projected timeline to commercialization and key milestones;
b) The addressable market for the Company's veterinary therapies; and
c) The Company's plans regarding acquisitions of veterinary clinics including their potential for generating near term revenue and as a distribution channel for the company's veterinary therapies.

Those interested in participating in the blogcast can do so by going to . 

Shareholders of Bio-Matrix Scientific Group Inc. (OTCBB:BMSN), the majority owner of Entest BioMedical Inc., are encouraged to participate in this blogcast, as this update pertains to both companies.

About Entest BioMedical Inc.:

Entest BioMedical is a developer of veterinary medicines that harness the animal's own reparative/immunological mechanisms. The company's products include immunotherapeutic cancer vaccines for canines (ImenVax™ I, II & III) and a stem cell therapy treatment for Chronic Obstructive Pulmonary Disease (COPD) in thoroughbred race horses (ENT-576™). The company's immuno-therapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure. The immuno-therapeutic cancer vaccine utilizes the animal's own cancer cells in order to induce an immune response. The company's proprietary ENT-576™ program for COPD incorporates "homing" stimulator technology that directs stem cells to diseased lung tissue. This approach could cause damaged tissue to regenerate with potential to alleviate symptoms and reverse lung damage.


This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

CONTACT: Crescendo Communications, LLC Investor Relations: David K. Waldman John J. Quirk (212) 671-1020 ENTB@crescendo-ir.com